Physician

Ofobuike Okani, M.D.

According to 2025 Medicare claims, Ofobuike Okani, M.D. (NPI: 1821104431) practices hematology/oncology in the Waco, TX market, with the plurality of this provider's patient population coming from Mc Lennan, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76712-6985. Okani is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Okani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 401 traditional Medicare patients, billed 95,198 HCPCS/CPT codes, and received $1,176,514 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,581 prescription claims across 223 beneficiaries totaling $3,155,312 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 62 claims. Open Payments data shows 17 records totaling $473. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,308,796 to $3,155,312. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	525	145,250	$1,398,869
2016	592	103,204	$1,546,602
2017	583	94,693	$1,279,906
2018	568	84,901	$1,588,133
2019	524	101,840	$1,431,361
2020	491	90,515	$1,139,016
2021	443	102,238	$1,271,299
2022	408	90,985	$1,332,505
2023	387	93,860	$1,133,701
2024	401	95,198	$1,176,514

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	174	1,195	$1,308,796
2016	168	1,211	$1,712,789
2017	163	1,163	$1,348,575
2018	184	1,228	$1,306,158
2019	160	917	$1,147,975
2020	194	1,239	$2,193,844
2021	193	1,210	$2,393,898
2022	184	1,227	$2,517,047
2023	186	1,428	$2,724,249
2024	223	1,581	$3,155,312

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	60	$38,029
2016	N/R	48	$21,076
2017	N/R	56	$17,949
2018	N/R	53	$6,082
2019	N/R	40	$6,349
2020	N/R	54	$3,391
2021	N/R	61	$4,169
2022	N/R	71	$2,438
2023	N/R	22	$7,050
2024	N/R	62	$2,245

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	67	67	$153
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	294	770	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	299	747	$12
36415	Insertion of needle into vein for collection of blood sample	271	1,037	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	263	841	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	37	1,036	$603,357
Brukinsa	Zanubrutinib	38	1,118	$541,790
Revlimid	Lenalidomide	25	679	$452,417
Kisqali	Ribociclib Succinate	23	644	$392,792
Lenalidomide	Lenalidomide	22	497	$264,181

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	35	$1,749
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$473	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ofobuike Okani, M.D.?

Tedicare shows public-source Medicare data for Ofobuike Okani, M.D. (NPI 1821104431), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ofobuike Okani, M.D. have ACO affiliation data?

Ofobuike Okani, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Ofobuike Okani, M.D.?

Ofobuike Okani, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Ofobuike Okani, M.D. have Open Payments data?

Ofobuike Okani, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.